Antibes

Researchers are studying high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia with multilineage dysplasia (AML-DML), conditions common in older adults that can progress to acute leukemia. This trial focuses on understanding how the drug Azacitidine works at the molecular level, especially its effects on cell death processes such as apoptosis and autophagy. The study also aims to explore ways to overcome resistance to Azacitidine by using other drugs that target these cell death pathways. Participants in this study will have high-risk MDS or AML-DML and will have received at least three to six cycles of Azacitidine treatment. The research involves investigating how Azacitidine causes DNA changes and affects cell survival, as well as studying the molecular mechanisms behind resistance to this drug. The trial may involve testing new molecules that can trigger different types of cell death to potentially reverse resistance. During the study, researchers will monitor participants to assess their hematological response at three and six months after treatment. This includes measuring changes in blood counts and other markers of disease activity. Participants will provide informed consent before joining, and their response to treatment will be carefully evaluated to better understand the drug's effects and resistance patterns.

Researchers are conducting a long-term observational study to understand patients with Chronic Obstructive Pulmonary Disease (COPD) who are treated with dupilumab as part of routine care. The study aims to gather information on patient characteristics, safety, and patient-reported outcomes over time. This study includes adults with uncontrolled COPD despite standard treatments and elevated blood eosinophil levels, reflecting real-world use of dupilumab. Participants will be followed for approximately 36 months at up to 50 sites in France. This study is non-interventional, meaning it observes patients receiving dupilumab as prescribed by their doctors without altering treatment. It collects data retrospectively and prospectively from patients newly starting dupilumab under approved guidelines for COPD. During the study, researchers will analyze various baseline and historical clinical data, including demographics, medical history, lung function, symptom patterns, exacerbations, inflammatory markers, comorbidities, and treatment history. Safety and patient-reported measures will also be assessed over the follow-up period. The study will provide detailed descriptive statistics to better characterize this patient population and the long-term outcomes of dupilumab treatment in COPD.

Researchers are evaluating capillary lactatemia as a potential tool to predict outcomes in patients with severe polytrauma during the pre-hospital phase. Current methods to assess trauma severity, such as vital signs and existing scoring systems, have limitations and can be subjective. Capillary lactatemia is a quick, safe test that can be performed at the accident scene and may improve the ability to triage patients effectively before hospital arrival. The study involves collecting capillary blood samples during hospital transfer to measure lactatemia values at inclusion and six hours later. This biological intervention aims to determine if capillary lactatemia can serve as an objective marker for poor outcomes in polytrauma patients. The study focuses on patients requiring emergency medical services and transfer to an emergency facility with medical assistance. Participants will be assessed through capillary blood sampling during transport, and their lactatemia levels will be recorded immediately and six hours after inclusion. Researchers will monitor these measurements alongside clinical data to evaluate the predictive value of capillary lactatemia. The study will help improve patient referral and management strategies in pre-hospital trauma care.